After agreeing to swallow Celgene for a whopping $74 billion, Bristol-Myers Squibb trumpeted the idea that pairing its solid-tumor expertise with Celgene’s hematology expertise could create a leading cancer drugmaker. But the legacy BMS business had some hematology expertise of
read moreA Chinese OTC drugmaker gets the distinction of ringing in the new year as the first company to be slapped with an FDA warning letter. More: FDA wrath falls on Chinese OTC maker of children’s drugs Source: fierce
read moreBristol-Myers Squibb has been waiting years to get a crack at the previously untreated non-small cell lung cancer market, but the end to its waiting may finally be in sight. And with an FDA priority review to speed things up,
read moreMerck was dealt a blow earlier this month when I-O superstar Keytruda missed its mark in a key late-stage trail for small-cell lung cancer. Now, in head and neck cancer, Keytruda faces pushback from England’s cost watchdog, which handed out
read moreAfter a manufacturing delay, Bluebird Bio has officially launched Zynteglo, its first gene therapy. And Nicola Heffron, a former Celgene exec, is tasked with charting the commercial course in Europe, its first proving ground, while the company works toward approval
read moreThe industry currently supports over 3,000 jobs, with 1,700 roles in manufacturing and bioprocessing. More: UK cell and gene clinical trials up 45% from 2018 Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals